Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001558370-25-000366
Filing Date
2025-01-23
Accepted
2025-01-23 17:00:20
Documents
14
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-K/A otlk-20240930x10ka.htm   iXBRL 10-K/A 635470
2 EX-31.2 otlk-20240930xex31d2.htm EX-31.2 7647
  Complete submission text file 0001558370-25-000366.txt   885141

Data Files

Seq Description Document Type Size
3 EX-101.SCH otlk-20240930.xsd EX-101.SCH 3441
4 EX-101.LAB otlk-20240930_lab.xml EX-101.LAB 24881
5 EX-101.PRE otlk-20240930_pre.xml EX-101.PRE 15646
16 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20240930x10ka_htm.xml XML 8322
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-K/A | Act: 34 | File No.: 001-37759 | Film No.: 25550856
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)